Bromfenac Sodium

• CAS: 91714-93-1
• Catalog Number: ACM91714931
• Category: Bromine Series

Custom Q&A

What is the molecular formula of bromfenac sodium?

The molecular formula of bromfenac sodium is C15H11BrNNaO3.

What is the molecular weight of bromfenac sodium?

The molecular weight of bromfenac sodium is 356.15 g/mol.

What is the parent compound of bromfenac sodium?

The parent compound of bromfenac sodium is bromfenac.

What are the synonyms of bromfenac sodium?

The synonyms of bromfenac sodium include BROMFENAC SODIUM, BromSite, and Bronuck.

What is the description of bromfenac sodium?

Bromfenac sodium is a non-steroidal anti-inflammatory drug and a non-narcotic analgesic. It is the sodium salt form of bromfenac.

What is the role of bromfenac sodium as a drug?

Bromfenac sodium binds to and inhibits the activity of cyclooxygenase II (COX II), an enzyme involved in inflammation. It prevents vasodilation, leukocytosis, disruption of the blood-aqueous humor barrier, and an increase in intraocular pressure.

What is the IUPAC name of bromfenac sodium?

The IUPAC name of bromfenac sodium is sodium;2-[2-amino-3-(4-bromobenzoyl)phenyl]acetate.

What is the InChIKey of bromfenac sodium?

The InChIKey of bromfenac sodium is HZFGMQJYAFHESD-UHFFFAOYSA-M.

What is the CAS number of bromfenac sodium?

The CAS number of bromfenac sodium is 91714-93-1.

What is the molecular weight and exact mass of bromfenac sodium?

The molecular weight and exact mass of bromfenac sodium are both 356.15 g/mol.

Synthetic Use

Upstream Synthesis Route 1

• 91713-91-6

• 91714-93-1

Reference: [1] Patent: CN108569975, 2018, A, . Location in patent: Paragraph 0034; 0039; 0040

Upstream Synthesis Route 2

• 1140-17-6

• 91714-93-1

Reference: [1] Patent: CN106957237, 2017, A,

Upstream Synthesis Route 3

• 92433-07-3

• 91714-93-1

Reference: [1] Patent: CN106957237, 2017, A,

Upstream Synthesis Route 4

• 91714-50-0

• 91714-93-1

Reference: [1]Current Patent Assignee: GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD. - CN104177272, 2016, B
[2]Current Patent Assignee: YANGTZE RIVER PHARMACEUTICAL GROUP CO LTD - CN108569975, 2018, A
[3]Current Patent Assignee: QILU PHARMACEUTICAL GROUP CO LTD - CN110172036, 2019, A

Upstream Synthesis Route 5

• 1140-17-6

• 91714-93-1

Reference: [1]Patent: CN106957237,2017,A